PetIQ, Inc. PETQ
PetIQ's grey-market vet-drug margins and rebate-dependent earnings are unsustainable as Merial goes direct-to-retail, while a $200M wellness-center cash burn and the CEO's Petters/Fleming ties imply 75-90% downside.
Thesis
Spruce Point argues PetIQ is a low-quality JOBS Act IPO trading at a 140% premium to pharmaceutical distributors despite occupying an ethically questionable grey-market niche that resells diverted veterinary drugs. Over 100% of FY17 pro-forma earnings came from vendor rebates now threatened as Merial sells Frontline directly to retailers, putting unsustainable 14.8% product-segment gross margins (vs. a 5.2% pharma-distributor median) at risk. Management's plan to roll out 1,000 in-store wellness centers in Walmart and other retailers will burn over $200M of cash through FY23 while at best achieving break-even by then. CEO McCord 'Cord' Christensen, whose bio omits the facts, was a 'longtime friend' of Tom Petters who funneled millions into the $3.65B Ponzi scheme, then served at Fleming Corp during the accounting fraud nicknamed 'Flem-ron'. Spruce Point models per-share value of $2.18 (bear) to $7.85 (bull) versus the $30.45 stock — 75-90% downside.
SCQA
PetIQ is a recent JOBS Act IPO marketed as a 'humanization of pets' growth story, distributing OTC and Rx veterinary drugs into Walmart and big-box retailers, with a planned rollout of 1,000 in-store wellness centers.
Over 100% of FY17 pro-forma earnings came from vendor rebates now under threat as Merial sells Frontline direct-to-retail; the wellness rollout will burn $200M+ of cash; and the CEO has undisclosed ties to the Petters Ponzi and Fleming Corp accounting fraud.
Sell PETQ. Spruce Point argues rebate-dependent margins, aggressive non-GAAP add-backs that strip out wellness launch costs, and unproven unit economics will reset toward pharmaceutical-distributor multiples once the Street loses faith in management's guidance.
Valuing PetIQ at 8-10x FY20 EBITDA in line with pharmaceutical-distributor and pet-care peer multiples implies $2.18 (bear) to $7.85 (bull) per share, or 74-93% downside from the $30.45 current price.
The three reasons
- 1
Over 100% of FY17 pro-forma earnings came from vendor rebates now at risk as Merial sells Frontline direct-to-retail
- 2
Wellness-center rollout (1,000 stores by FY23) will burn $200M+ of cash and barely break even
- 3
CEO Cord Christensen has undisclosed ties to the Petters Ponzi scheme and Fleming Corp accounting fraud
Primary demands
- Sell PETQ shares — Strong Sell rating with 75-90% downside
- Discount management's non-GAAP adjustments that strip out wellness-center launch costs
- Reassess sustainability of product-segment gross margins as Merial bypasses grey-market distributors
- Demand fuller disclosure of CEO Christensen's ties to the Petters Ponzi scheme and Fleming Corp fraud
KPIs cited
Pattern membership
Precedents cited
- Petters $3.65B Ponzi scheme
- Fleming Corp accounting fraud ('Flem-ron')
- W.T.F. Wholesale / True Science Holdings precursor entities
Composition what's on the 96 slides
Slide gallery ·
Notes
Classic Spruce Point short report: 96-page deep-dive layering five distinct attack lines (fraud-adjacent CEO history, grey-market business risk, vendor-rebate earnings dependency, unsustainable peer-margin gap, and cash-burning wellness rollout). Cover is unusually creative — a 3D-rendered streetscape with 'WTF Petcare' storefront and 'Danger: Flea and tick infested investment' signage — far more memorable than the templated body slides. Author not named on cover (Spruce Point reports historically authored by Ben Axler but unconfirmed in the pages sampled). Stake not disclosed beyond the standard 'short position' disclaimer. The CEO-history pages 13-15 (Christensen / Petters / Fleming) and the peer-gap chart on p. 41 are the most narratively distinctive slides for a swipe file.